These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 9592387)
1. The Cambrian period of nonviral gene delivery. Wolff JA; Trubetskoy VS Nat Biotechnol; 1998 May; 16(5):421-2. PubMed ID: 9592387 [No Abstract] [Full Text] [Related]
2. Emerging vectors and targeting methods for nonviral gene therapy. Lavigne MD; Górecki DC Expert Opin Emerg Drugs; 2006 Sep; 11(3):541-57. PubMed ID: 16939390 [TBL] [Abstract][Full Text] [Related]
3. Non-viral gene delivery systems. Davis ME Curr Opin Biotechnol; 2002 Apr; 13(2):128-31. PubMed ID: 11950563 [TBL] [Abstract][Full Text] [Related]
4. Current Status of Nonviral Vectors for Gene Therapy in China. Liu L; Yang J; Men K; He Z; Luo M; Qian Z; Wei X; Wei Y Hum Gene Ther; 2018 Feb; 29(2):110-120. PubMed ID: 29320893 [TBL] [Abstract][Full Text] [Related]
5. Impact of DNA vector topology on non-viral gene therapeutic safety and efficacy. Sum CH; Wettig S; Slavcev RA Curr Gene Ther; 2014; 14(4):309-29. PubMed ID: 25039613 [TBL] [Abstract][Full Text] [Related]
6. [Advances in cationic polymers used as nonviral vectors for gene delivery]. Ren X; Yang L; Liang X; Liu Z; Deng Y Sheng Wu Gong Cheng Xue Bao; 2013 May; 29(5):568-77. PubMed ID: 24010355 [TBL] [Abstract][Full Text] [Related]
7. Muscular gene transfer using nonviral vectors. Braun S Curr Gene Ther; 2008 Oct; 8(5):391-405. PubMed ID: 18855634 [TBL] [Abstract][Full Text] [Related]
9. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Plank C; Mechtler K; Szoka FC; Wagner E Hum Gene Ther; 1996 Aug; 7(12):1437-46. PubMed ID: 8844203 [TBL] [Abstract][Full Text] [Related]
10. Controlled release systems for DNA delivery. Pannier AK; Shea LD Mol Ther; 2004 Jul; 10(1):19-26. PubMed ID: 15233938 [TBL] [Abstract][Full Text] [Related]
11. Synergistic effects in gene delivery-a structure-activity approach to the optimisation of hybrid dendritic-lipidic transfection agents. Jones SP; Gabrielson NP; Pack DW; Smith DK Chem Commun (Camb); 2008 Oct; (39):4700-2. PubMed ID: 18830464 [TBL] [Abstract][Full Text] [Related]
12. Dendritic poly(L-lysine)-b-Poly(L-lactide)-b-dendritic poly(L-lysine) amphiphilic gene delivery vectors: roles of PLL dendritic generation and enhanced transgene efficacies via termini modification. Li Y; Zhu Y; Xia K; Sheng R; Jia L; Hou X; Xu Y; Cao A Biomacromolecules; 2009 Aug; 10(8):2284-93. PubMed ID: 19586045 [TBL] [Abstract][Full Text] [Related]
13. Editorial: Current Gene Therapy on Non-viral Gene Delivery and Therapy. Peng L Curr Gene Ther; 2018; 18(1):2. PubMed ID: 29769001 [No Abstract] [Full Text] [Related]
14. Nonviral Delivery Systems for Cancer Gene Therapy: Strategies and Challenges. Shim G; Kim D; Le QV; Park GT; Kwon T; Oh YK Curr Gene Ther; 2018; 18(1):3-20. PubMed ID: 29357792 [TBL] [Abstract][Full Text] [Related]
15. Hybrids of nonviral vectors for gene delivery. Zhang S; Zhao Y; Zhao B; Wang B Bioconjug Chem; 2010 Jun; 21(6):1003-9. PubMed ID: 20205418 [TBL] [Abstract][Full Text] [Related]